SG11201407229UA - Substituted pyrazole compounds as lpar antagonists - Google Patents

Substituted pyrazole compounds as lpar antagonists

Info

Publication number
SG11201407229UA
SG11201407229UA SG11201407229UA SG11201407229UA SG11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA
Authority
SG
Singapore
Prior art keywords
international
new jersey
pct
compounds
designated states
Prior art date
Application number
SG11201407229UA
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407229U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201407229UA publication Critical patent/SG11201407229UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201407229UA 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists SG11201407229UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
SG11201407229UA true SG11201407229UA (en) 2014-12-30

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407229UA SG11201407229UA (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US20150259295A1 (ko)
EP (1) EP2864294A1 (ko)
JP (1) JP2015520201A (ko)
KR (1) KR20150011003A (ko)
CN (1) CN104411690A (ko)
AU (1) AU2013279510A1 (ko)
BR (1) BR112014031108A2 (ko)
CA (1) CA2869602A1 (ko)
CL (1) CL2014003242A1 (ko)
CO (1) CO7160077A2 (ko)
CR (1) CR20140516A (ko)
EA (1) EA201492283A1 (ko)
HK (1) HK1206341A1 (ko)
IL (1) IL236091A0 (ko)
IN (1) IN2014DN09347A (ko)
MA (1) MA37765A1 (ko)
MX (1) MX2014014105A (ko)
PE (1) PE20142445A1 (ko)
PH (1) PH12014502364A1 (ko)
SG (1) SG11201407229UA (ko)
UA (1) UA109867C2 (ko)
WO (1) WO2013189862A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
BR112020011953A2 (pt) * 2017-12-19 2020-11-17 Bristol-Myers Squibb Company ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240005892A (ko) * 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および/または治療剤
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
PH12014502364A1 (en) 2015-01-12
WO2013189862A1 (en) 2013-12-27
EA201492283A1 (ru) 2015-04-30
BR112014031108A2 (pt) 2017-06-27
CO7160077A2 (es) 2015-01-15
US20150259295A1 (en) 2015-09-17
IN2014DN09347A (ko) 2015-07-17
HK1206341A1 (en) 2016-01-08
AU2013279510A1 (en) 2014-10-16
CL2014003242A1 (es) 2015-03-20
MX2014014105A (es) 2015-03-05
EP2864294A1 (en) 2015-04-29
MA37765A1 (fr) 2017-04-28
UA109867C2 (ru) 2015-10-12
PE20142445A1 (es) 2015-01-28
KR20150011003A (ko) 2015-01-29
CA2869602A1 (en) 2013-12-27
CN104411690A (zh) 2015-03-11
CR20140516A (es) 2014-12-01
JP2015520201A (ja) 2015-07-16
IL236091A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201407229UA (en) Substituted pyrazole compounds as lpar antagonists
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201408094YA (en) Neprilysin inhibitors
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408238WA (en) Substituted tricyclic compounds as fgfr inhibitors
SG11201408173WA (en) Pyrimidinyl tyrosine kinase inhibitors
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201408232RA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof